Gland Pharma Limited — Q3 FY26
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,695 crore, up 22% YoY, driven by broad-based growth across markets and a turnaround at Synexi.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Senexi EBITDA breakeven in Q3 FY26
Senexi is expected to achieve EBITDA breakeven in Q3 FY26, supported by €50M quarterly revenue target.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1